The chemical industry promised that newer “short-chain” PFAS would be safer—but emerging science suggests these replacement “forever chemicals” may be just as dangerous, and even harder to track. Action Alert!
Listen to the audio version of this article:
THE TOPLINE
- While older PFAS chemicals are declining in wildlife following phase-outs, newer short-chain PFAS now dominate environmental contamination—and scientists still don’t fully understand where they accumulate or how they impact human health.
- Research shows short-chain PFAS can cross the placenta more easily, penetrate the skin efficiently, and break down into persistent metabolites that may linger in the body far longer than industry claims suggest.
- Regulating PFAS one chemical at a time has failed. As companies continue introducing new formulations faster than science can evaluate them, we need a comprehensive ban on PFAS as a class.
For years, chemical manufacturers defended a massive transition away from older “legacy” PFAS chemicals like PFOA and PFOS by arguing that newer “short-chain” PFAS were safer. These replacement chemicals, industry claimed, would accumulate less in the body and break down more easily in the environment.
But a growing body of research suggests this new generation of PFAS chemicals are still a public health threat.
A recent study examining PFAS contamination in pilot whales near the Faroe Islands highlights this reality: while older PFAS are declining in marine wildlife—as expected after these chemicals have been phased out—the newer short-chain PFAS are largely absent. Scientists now find themselves asking an unsettling question: If these chemicals aren’t showing up in whales and the open ocean, where are they—or their metabolites or breakdown products—going?
The “Regrettable Substitution” Problem
For decades, two long-chain PFAS chemicals — PFOA (used in Teflon®) and PFOS (used in Scotchgard®) — were the flagship “forever chemicals.” When mounting evidence linked them to cancer, thyroid disruption, immune damage, and reproductive harm, public pressure and litigation finally forced manufacturers to phase them out in the early 2000s.
The replacements were shorter-chain PFAS compounds — molecules with fewer fluorinated carbons. Industry told us that these newer chemicals would behave similarly in industrial applications but break down faster in the environment and accumulate less in living tissue.
Today, short-chain PFAS now account for 88.8% of total PFAS detected in the water column. They are everywhere. And the science catching up to them is telling a troubling story.
What the Whale Study Found — and Didn’t Find
The whale study referenced above analyzed tissue samples from Faroese pilot whales collected between 2001 and 2023 and found concentrations of legacy PFAS have declined in the whale tissue, confirming that bans on the old compounds are working.
The disturbing news: newer PFAS are essentially absent from the whales — but not because they’re absent from the environment. Production of novel PFAS is higher than ever. These chemicals are going somewhere. But where?
Two possibilities have emerged, and both are alarming in different ways.
One theory is that novel PFAS may be accumulating closer to their sources — near manufacturing facilities, in coastal waters, and in communities near industrial sites. A parallel study of beluga whales in Canada’s St. Lawrence Estuary found increasing concentrations of newer, unregulated PFAS from 2000 to 2017, while legacy PFAS declined. The estuary sits near human communities and PFAS manufacturing sources. What’s in those whales could reflect what’s in nearby people.
Another theory is that short-chain PFAS may actually travel farther and more easily than their predecessors — transported through the atmosphere in rain and snowfall, spreading globally before anyone can track them. For example, short-chain PFAS from the GenX platform, used as replacements for PFOA produced by Chemours (the US spin-off from DuPont, the original inventor of—and current manufacturer—Teflon®), was detected in the Arctic Ocean in 2020. These short-chain PFAS had already spread to the most remote corners of the planet.
Either way, we’re being exposed. Studies of human tissue increasingly show a high proportion of unidentifiable organofluorine chemicals — compounds so new that scientists don’t yet have the tools to name them.
Breaking Down the Science: What Short-Chain PFAS Actually Do in Your Body
The chemical industry’s case for short-chain PFAS rests on data derived from what are called ADME studies — that reveal how a substance is Absorbed, Distributed, Metabolized, and Excreted. On paper, short-chain compounds look less dangerous: they clear the body faster than long-chain PFAS. But when you look closer, the picture becomes far more complicated toxicologically.
They Get In More Easily Than You’d Think
Short-chain PFAS don’t just enter your body through drinking water or food. They’re absorbed through skin contact at surprisingly high rates. With some short-chain PFAS compounds, around half of what touches your skin can enter your bloodstream.
By contrast, older long-chain PFAS are actually less likely to pass through the skin — they tend to sit in skin tissue instead. Shorter chains slide through more readily. If you’re touching PFAS-treated fabrics, non-stick cookware, stain-resistant carpets, or cosmetics (and you almost certainly are), short-chain PFAS have an easier path into your body than their predecessors did.
They Reach Where It Matters Most: Your Blood, Liver, and Unborn Children
Once absorbed, short-chain PFAS distribute rapidly through the body, concentrating in the blood, liver, skin, and kidneys. One key compound, perfluorohexanoic acid (PFHxA), shows a strong preference for whole blood — meaning it travels efficiently throughout the circulatory system. PFHxA has also been shown to cross the placenta at a rate that is six times higher than that of the long-chain PFDA. This means a pregnant person’s exposure to short-chain PFAS translates into significant fetal exposure — at the most vulnerable stage of human development.
“Fast Clearance” Hides a Dangerous Secret
The industry has long pointed to shorter half-lives as evidence of safety. PFHxA, for example, clears from rodents in about 2–3 hours. In humans, estimates range from 14 to 49 days — far shorter than PFOA’s average of 3.5 years or PFHxS’s 5 to 9 years.
But here’s what that talking point leaves out: it’s not just about the parent compound.
Many short-chain PFAS — particularly fluorotelomers like 6:2 FTOH, used extensively in food packaging — are precursors. Your body metabolizes them into breakdown products, and those breakdown products may behave very differently than the parent compound. One metabolite, called the 5:3 acid, is highly biopersistent. In animal studies, it takes approximately one year to reach a steady state in plasma and liver tissue: hardly “fast clearance.”
Studies published in peer-reviewed journals found that 6:2 FTOH — one of the most widely used short-chain PFAS, found in most plastic coatings on food wrappers — accumulates in the fat, liver, and plasma of rats and persists for over a year. This research also found that chemical industry safety assessments were based on just one metabolite (PFHxA) while ignoring other, more toxic breakdown products.
The result: human health risk from 6:2 FTOH—and shorter chain PFAS more generally—has been significantly underestimated.
Researchers studying PFAS face a “chemical Whac-A-Mole”: by the time scientists understand one compound well enough to regulate it, companies have already moved on to the next formulation. Patent applications are already being filed for PFAS chemistries that scientists say are “nothing like we have seen before” — compounds that could begin entering our environment in the next five to ten years.
There could be millions of possible PFAS formulations. Regulating them one chemical at a time is not a safety strategy. It is a gamble with our health and our lives.
Ban PFAS as a Class
ANH-USA has long called for a comprehensive ban on PFAS chemicals and the development of genuinely safer alternatives. The short-chain PFAS story illustrates exactly why a chemical-by-chemical regulatory approach fails the public.
We’ve documented the backsliding under the current Administration on what few PFAS safety standards have been set. But we must start moving beyond drinking water limits on a handful of named compounds.
It’s time to stop playing chemical Whac-A-Mole. Ban PFAS as a class, and build something genuinely better.
Action Alert!
